0
Give Kids a Chance Act of 2023
3/8/2024, 3:54 PM
Summary of Bill S 2897
The bill proposes several key initiatives to achieve this goal. Firstly, it calls for increased funding for after-school programs, summer learning opportunities, and other extracurricular activities that can help children in underserved communities stay engaged and motivated in their education. Additionally, the bill aims to expand access to high-quality early childhood education programs, such as pre-kindergarten, to ensure that all children have a strong foundation for learning.
Furthermore, the Give Kids a Chance Act of 2023 includes provisions to support teachers and school staff in these communities, such as professional development opportunities and incentives to attract and retain high-quality educators. The bill also emphasizes the importance of parental involvement in children's education and includes measures to increase communication and collaboration between schools and families. Overall, the Give Kids a Chance Act of 2023 seeks to address the disparities in educational opportunities that exist for children in low-income communities and provide them with the support they need to succeed. By investing in programs and initiatives that promote academic achievement and holistic development, this bill aims to give all children a fair chance at a bright future.
Congressional Summary of S 2897
Give Kids a Chance Act of 2023
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer.
Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations so as to authorize investigations of new drugs that are used in combination with active ingredients that have already been approved and that (1) have been determined to be the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.
The Food and Drug Administration must issue guidance and report on the bill's implementation. The Government Accountability Office must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.



